AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read$PRCT

PROCEPT BioRobotics Corporation (PRCT) Sets Q3 2026 Results Date

PROCEPT BioRobotics (PRCT) will release Q3 2026 earnings after market close on Nov. 4, 2026, followed by a conference call. The announcement is a routine scheduling notice.

Original reporting
tradingview.com
Published Oct 12, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
PROCEPT BioRobotics Corporation (PRCT) Sets Q3 2026 Results Date — source image
Source · tradingview.com
Decision brief

The 30-second read

$PRCTNeutralLow
01

Why it matters

The release date itself is a routine corporate disclosure with limited trading relevance until the actual results are posted.

02

Market read

Low relevance; the article serves as a calendar reminder rather than a catalyst.

03

What to watch

Potential hidden guidance hints in the upcoming call could move the stock, but not evident from this notice.

Relevance 4/10Novelty 3/10Timing: after market close on Nov 4, 2026

Background

PROCEPT BioRobotics is a medical device company focused on robotic-assisted prostate procedures. The Q3 2026 earnings are expected later this year.

Company-level read

Ticker impact

$PRCTNeutralHigh confidence
Context

PROCEPT BioRobotics announced the date and time for its Q3 2026 earnings release (Nov 4 after market close).

Expected impact

likely neutral as the market awaits the actual results; no directional pressure anticipated.

Evidence & confidence

Only the release timing is disclosed; without numbers or guidance, traders have no actionable catalyst.

Market effects

Sector

None significant; the announcement does not affect the broader medtech sector.

Regional

No regional effect expected.

Global

Limited to investors tracking PROCEPT BioRobotics.

Counterpoint

What could challenge this read

If the market overreacts to the mere scheduling, a short position could capture a quick pullback.

Key entities

  • company
    PROCEPT BioRobotics Corporation

    Medical device manufacturer (ticker PRCT).

Read at source← All news

Related articles

AUG 6
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com6 min
JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min